A Phase 1/2 interventional study of Etoricoxib 75 mg 4% DMSO Gel and Etoricoxib 75 mg 4% PG Gel in Osteoarthritis Pain, sponsored by Organon and Co. Completed. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-06-27.
Sponsored by Organon and Co · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Osteoarthritis by Organon & Co. — none open to participants now, none under way, none of them phase 3. Osteoarthritis · Organon & Co..
Among the 15 studies in Osteoarthritis by Organon & Co., this one is the 11th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2013, is the only one in phase 1/2, and was the 15th registered.
2,975 studies on the registry are indexed under Osteoarthritis; 435 are open to participants now.
Browse Osteoarthritis studies →None of the 15 studies in Osteoarthritis by Organon & Co. is open now. The open studies under Osteoarthritis, anywhere →
Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 8 · Phase 4 2
First in 1998; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is below the median of 80 across 2,239 interventional studies indexed under Osteoarthritis.
Median enrollment 508 across the 12 interventional studies, 1,261 across the 3 observational. Of the 14 that completed or were terminated, 4 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Osteoarthritis by Organon & Co., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study Part 1 is designed to assess the plasma pharmacokinetics of etoricoxib (ETOR) 4% dimethyl sulfoxide (DMSO) and propylene glycol (PG) formulations, each at 2 different doses, upon single-dose topical administration on the knee of osteoarthritis participants. Study Part 2 is designed to evaluate the efficacy of topical etoricoxib vs. placebo in the treatment of osteoarthritis of the knee. The primary hypothesis is that topical etoricoxib will be more effective than placebo in the treatment of osteoarthritis of the knee over 2 weeks of treatment as assessed by time-weighted average change from baseline on the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Visual Analogue (VA) 3.0 pain subscale.
Part I of the study will consist of a single-dose, open-label, randomized, four-way cross over study with topical administration of etoricoxib gel on the knee of osteoarthritis participants. The washout between successive dose administrations will be at least one week. Part 2 of the study will consist of double-blind, randomized, placebo-controlled, parallel groups, multiple dose, twice daily topical administration of etoricoxib or placebo gel on the knee of osteoarthritis participants for a period of two weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel. All treatments were applied topically.
Drug: Etoricoxib 75 mg 4% DMSO Gel · Drug: Etoricoxib 75 mg 4% PG Gel · Drug: Etoricoxib 150 mg 4% DMSO Gel · Drug: Etoricoxib 150 mg 4% PG Gel
Single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel. All treatments were applied topically.
Drug: Etoricoxib 75 mg 4% DMSO Gel · Drug: Etoricoxib 75 mg 4% PG Gel · Drug: Etoricoxib 150 mg 4% DMSO Gel · Drug: Etoricoxib 150 mg 4% PG Gel
Single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel. All treatments were applied topically.
Drug: Etoricoxib 75 mg 4% DMSO Gel · Drug: Etoricoxib 75 mg 4% PG Gel · Drug: Etoricoxib 150 mg 4% DMSO Gel · Drug: Etoricoxib 150 mg 4% PG Gel
Single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel. All treatments were applied topically.
Drug: Etoricoxib 75 mg 4% DMSO Gel · Drug: Etoricoxib 75 mg 4% PG Gel · Drug: Etoricoxib 150 mg 4% DMSO Gel · Drug: Etoricoxib 150 mg 4% PG Gel
Single-dose etoricoxib 163 mg (4.30 mL) 4% DMSO gel (DMSO formulation administered in error/overdose \[OD\]), followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel. All treatments were applied topically.
Drug: Etoricoxib 75 mg 4% DMSO Gel · Drug: Etoricoxib 75 mg 4% PG Gel · Drug: Etoricoxib 150 mg 4% DMSO Gel · Drug: Etoricoxib 163 mg 4% DMSO gel
Participants randomized to a treatment sequence in Part 1 who received single dose placebo gel (1.97 or 3.94 mL) applied topically in error instead of active study drug and dropped out after the first treatment period in the sequence. Included in the safety assessments only.
Drug: Placebo
Etoricoxib 50 mg (1.31 mL, 4% DMSO gel) applied topically twice daily to the affected knee for a period of 2 weeks.
Drug: Etoricoxib 50 mg 4% DMSO
Matching placebo to etoricoxib 50 mg 1.31 mL 4% DMSO gel applied topically twice daily to the affected knee for a period of 2 weeks.
Drug: Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel
Etoricoxib 75 mg 4% DMSO gel applied topically.
Etoricoxib 75 4% PG gel applied topically.
Etoricoxib 150 mg 4% DMSO gel applied topically.
Etoricoxib 150 mg 4% PG gel applied topically.
Etoricoxib 163 mg 4% DMSO gel applied topically
Placebo gel applied topically.
Etoricoxib 50 mg 4% DMSO gel applied topically.
Matching Placebo to Etoricoxib 50 mg 4% DMSO gel applied topically.
Study Part 1: Maximum Concentration (Cmax) of ETOR After Single Dosing
Cmax determined for the period up to 72 hours post-single application. Descriptive statistics are expressed as the geometric least squares mean (GLSM). Cmax with value 0 included in calculation of GLSMs with a value of 0.5\*LLOQ (=0.5 h\*ng/ml).
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, 24, 36, 48, and 72 hours post-application
Study Part 1: Time to Maximum Concentration (Tmax) of ETOR After Single Dosing
Tmax determined for the period up to 72 hours post-single application.
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, 24, 36, 48, and 72 hours post-application
Study Part 1: Area Under the Concentration-time Curve of ETOR From Time 0 to Last (AUC0-last) After Single Dosing
Area under the observed concentration-time curve from time zero to the last quantifiable time point determined for the period up to 72 hours post-single application. The area was calculated according to the linear up/log down trapezoidal rule. AUC0-last is an estimate of total plasma exposure. Descriptive statistics are expressed as the GLSM. AUC with value 0 included in calculation of GLSMs with a value of 0.5\*LLOQ (=0.5 h\*ng/ml).
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, 24, 36, 48, and 72 hours post-application
Study Part 2: Change From Baseline in Mean Participant Score on the Western Ontario and McMaster Universities Arthritis Index (WOMAC) Visual Analog (VA) 3.1 Pain Scale
The WOMAC VA 3.1 Pain subscale is a self-administered questionnaire assessing lower extremity pain due to osteoarthritis that was completed by participants 2 to 3 hours post morning dose. The WOMAC Pain Subscale had five questions with answers to each item assessed on a 100 mm VA scale (0 = no pain; 100 = extreme pain). The score for each item was summed and the overall score ranged from 0 to 500 (increasing severity). The time weighted average up to day x was calculated as the sum of rectangles under the curve for successive intervals prior to day x as defined by timepoints at which assessments were made. The time weighted change from baseline was calculated. A negative mean change from baseline indicates improvement in pain.
Time frame: Baseline (Day -1), Day 2, Day 4, Day 7, Day 11, Day 14
Study Part 2: Change From Baseline in Mean Participant Score on the WOMAC VA 3.1 Stiffness Scale
The WOMAC VA 3.1 Stiffness subscale is a self-administered questionnaire assessing lower extremity stiffness due to osteoarthritis that was completed by participants 2 to 3 hours post morning dose. The WOMAC Stiffness subscale had two questions with answers to each item assessed on a 100 mm VA scale (0 = no stiffness; 100 = extreme stiffness). The score for each item was summed and the overall score ranged from 0 to 200 (increasing severity). The time weighted average up to day x was calculated as the sum of rectangles under the curve for successive intervals prior to day x as defined by timepoints at which assessments were made. The time weighted change from baseline was calculated. A negative mean change from baseline indicates improvement in stiffness.
Time frame: Baseline (Day -1), Day 2, Day 4, Day 7, Day 11, Day 14
Study Part 2: Change From Baseline in Mean Participant Score on the WOMAC VA 3.1 Physical Functioning Scale
The WOMAC VA 3.1 Physical Functioning subscale is a self-administered questionnaire assessing lower extremity physical function due to osteoarthritis that was completed by participants 2 to 3 hours post morning dose. The WOMAC Physical Functioning subscale had 17 questions with answers to each item assessed on a 100 mm VA scale (0 = no difficulty; 100 = extreme difficulty). The score for each item was summed and the overall score ranged from 0 to 1700 (increasing severity). The time weighted average up to day x was calculated as the sum of rectangles under the curve for successive intervals prior to day x as defined by timepoints at which assessments were made. The time weighted change from baseline was calculated. A negative mean change from baseline indicates improvement in physical function.
Time frame: Baseline (Day -1), Day 2, Day 4, Day 7, Day 11, Day 14
Study Part 2: Percentage of Participants by Category on Patient Global Assessment of Response to Therapy (PGART)
The PGART is a self-administered questionnaire completed by participants. Participant assessment of response of arthritis to study medication was assessed on a 5-point Likert scale ('very well', 'well', 'fair', 'poor', and 'very poor').
Time frame: Day 2, Day 4, Day 7, Day 11, Day 14, post-trial (up to Day 28)
Study Parts 1 and 2: Number of Participants Who Experienced at Least One Adverse Event
An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.
Time frame: Study Part 1: up to Day 47; Study Part 2: up to Day 28
Study Parts 1 and 2: Number of Participants Who Discontinued Study Drug Due to an Adverse Event
An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.
Time frame: Study Part 1: up to Day 47; Study Part 2: up to Day 28
| Milestone | Pt 1: ETOR 75 DMSO/ETOR 150 PG/ETOR 75 PG/ETOR 150 DMSO | Pt 1: ETOR 75 PG/ETOR 75 DMSO/ETOR 150 DMSO/ETOR 150 PG | Pt 1: ETOR 150 DMSO/ETOR 75 PG/ETOR 150 PG/ETOR 75 DMSO | Pt 1: ETOR 150 PG/ETOR 150 DMSO/ETOR 75 PG/ETOR 75 DMSO | Pt 1: ETOR OD/ ETOR 150 DMSO/ ETOR 75 DMSO/ ETOR 75 PG | Pt 1: Placebo (Deviation) | Pt 2: ETOR 50 DMSO | Pt 2: Placebo |
|---|---|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 3 | 2 | 2 | 24 | 24 |
| Treated | 5 | 5 | 5 | 3 | 2 | 2 | 24 | 24 |
| Completed | 5 | 5 | 5 | 3 | 2 | 0 | 24 | 24 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
Cmax determined for the period up to 72 hours post-single application. Descriptive statistics are expressed as the geometric least squares mean (GLSM). Cmax with value 0 included in calculation of GLSMs with a value of 0.5\*LLOQ (=0.5 h\*ng/ml).
| mg | ETOR 75 DMSO | ETOR 75 PG | ETOR 150 DMSO | ETOR 150 PG | ETOR OD | Placebo (Pt 1) (Deviation) |
|---|---|---|---|---|---|---|
| Study Part 1: Maximum Concentration (Cmax) of ETOR After Single Dosing | 12.39 ± 8.24 | 2.43 ± 2.14 | 27.30 ± 15.30 | 3.74 ± 3.79 | — | — |
Tmax determined for the period up to 72 hours post-single application.
| hour | ETOR 75 DMSO | ETOR 75 PG | ETOR 150 DMSO | ETOR 150 PG | ETOR OD | Placebo (Pt 1) (Deviation) |
|---|---|---|---|---|---|---|
| Study Part 1: Time to Maximum Concentration (Tmax) of ETOR After Single Dosing | 30.0 (23.5 to 72.0) | 48.0 (1.0 to 72.0) | 24.0 (2.0 to 72.0) | 48 (24.0 to 72.0) | 36.0 (24.0 to 48.0) | — |
Area under the observed concentration-time curve from time zero to the last quantifiable time point determined for the period up to 72 hours post-single application. The area was calculated according to the linear up/log down trapezoidal rule. AUC0-last is an estimate of total plasma exposure. Descriptive statistics are expressed as the GLSM. AUC with value 0 included in calculation of GLSMs with a value of 0.5\*LLOQ (=0.5 h\*ng/ml).
| mg | ETOR 75 DMSO | ETOR 75 PG | ETOR 150 DMSO | ETOR 150 PG | ETOR OD | Placebo (Pt 1) (Deviation) |
|---|---|---|---|---|---|---|
| Study Part 1: Area Under the Concentration-time Curve of ETOR From Time 0 to Last (AUC0-last) After Single Dosing | 611.3 ± 400.97 | 65.6 ± 112.83 | 1309.7 ± 686.34 | 161.3 ± 172.96 | — | — |
The WOMAC VA 3.1 Pain subscale is a self-administered questionnaire assessing lower extremity pain due to osteoarthritis that was completed by participants 2 to 3 hours post morning dose. The WOMAC Pain Subscale had five questions with answers to each item assessed on a 100 mm VA scale (0 = no pain; 100 = extreme pain). The score for each item was summed and the overall score ranged from 0 to 500 (increasing severity). The time weighted average up to day x was calculated as the sum of rectangles under the curve for successive intervals prior to day x as defined by timepoints at which assessments were made. The time weighted change from baseline was calculated. A negative mean change from baseline indicates improvement in pain.
| Units on a scale | ETOR 50 DMSO | Placebo (Pt 2) |
|---|---|---|
| BL to Day 2 | -24.21 ± 76.88 | -37.21 ± 101.77 |
| BL to Day 4 | -34.29 ± 69.15 | -43.92 ± 94.81 |
| BL to Day 7 | -45.81 ± 67.92 | -54.11 ± 94.11 |
| BL to Day 11 | -59.42 ± 71.12 | -63.60 ± 90.99 |
| BL to Day 14 | -69.60 ± 75.81 | -72.60 ± 91.35 |
The WOMAC VA 3.1 Stiffness subscale is a self-administered questionnaire assessing lower extremity stiffness due to osteoarthritis that was completed by participants 2 to 3 hours post morning dose. The WOMAC Stiffness subscale had two questions with answers to each item assessed on a 100 mm VA scale (0 = no stiffness; 100 = extreme stiffness). The score for each item was summed and the overall score ranged from 0 to 200 (increasing severity). The time weighted average up to day x was calculated as the sum of rectangles under the curve for successive intervals prior to day x as defined by timepoints at which assessments were made. The time weighted change from baseline was calculated. A negative mean change from baseline indicates improvement in stiffness.
| Units on a scale | ETOR 50 DMSO | Placebo (Pt 2) |
|---|---|---|
| BL to Day 2 | -9.17 ± 37.44 | -16.79 ± 41.86 |
| BL to Day 4 | -14.69 ± 35.23 | -18.79 ± 39.29 |
| BL to Day 7 | -19.34 ± 35.75 | -23.08 ± 37.53 |
| BL to Day 11 | -24.44 ± 34.60 | -26.87 ± 35.26 |
| BL to Day 14 | -29.22 ± 36.64 | -30.52 ± 34.33 |
The WOMAC VA 3.1 Physical Functioning subscale is a self-administered questionnaire assessing lower extremity physical function due to osteoarthritis that was completed by participants 2 to 3 hours post morning dose. The WOMAC Physical Functioning subscale had 17 questions with answers to each item assessed on a 100 mm VA scale (0 = no difficulty; 100 = extreme difficulty). The score for each item was summed and the overall score ranged from 0 to 1700 (increasing severity). The time weighted average up to day x was calculated as the sum of rectangles under the curve for successive intervals prior to day x as defined by timepoints at which assessments were made. The time weighted change from baseline was calculated. A negative mean change from baseline indicates improvement in physical function.
| Units on a scale | ETOR 50 DMSO | Placebo (Pt 2) |
|---|---|---|
| BL to Day 2 | -117.13 ± 200.38 | -153.54 ± 278.66 |
| BL to Day 4 | -147.71 ± 183.07 | -171.35 ± 272.51 |
| BL to Day 7 | -172.94 ± 186.22 | -199.88 ± 265.29 |
| BL to Day 11 | -214.87 ± 203.95 | -245.05 ± 238.05 |
| BL to Day 14 | -250.82 ± 218.72 | -280.29 ± 233.39 |
The PGART is a self-administered questionnaire completed by participants. Participant assessment of response of arthritis to study medication was assessed on a 5-point Likert scale ('very well', 'well', 'fair', 'poor', and 'very poor').
| Percentage of participants | ETOR 50 DMSO | Placebo (Pt 2) |
|---|---|---|
| Day 2: Very well | 0.0 | 0.0 |
| Day 2: Well | 20.8 | 33.3 |
| Day 2: Fair | 25.0 | 25.0 |
| Day 2: Poor | 37.5 | 33.3 |
| Day 2: Very poor | 16.7 | 8.3 |
| Day 4: Very well | 0.0 | 0.0 |
| Day 4: Well | 20.8 | 33.3 |
| Day 4: Fair | 45.8 | 37.5 |
| Day 4: Poor | 29.2 | 25.0 |
| Day 4: Very poor | 4.2 | 4.2 |
| Day 7: Very well | 0.0 | 0.0 |
| Day 7: Well | 25.0 | 37.5 |
| Day 7: Fair | 50.0 | 37.5 |
| Day 7: Poor | 25.0 | 25.0 |
| Day 7: Very poor | 0.0 | 0.0 |
| Day 11: Very well | 0.0 | 0.0 |
| Day 11: Well | 37.5 | 50.0 |
| Day 11: Fair | 45.8 | 37.5 |
| Day 11: Poor | 16.7 | 12.5 |
| Day 11: Very poor | 0.0 | 0.0 |
| Day 14: Very well | 0.0 | 8.3 |
| Day 14: Well | 54.2 | 50.0 |
| Day 14: Fair | 41.7 | 33.3 |
| Day 14: Poor | 4.2 | 8.3 |
| Day 14: Very poor | 0.0 | 0.0 |
| Post-trial: Very well | 8.3 | 8.3 |
| Post-trial: Well | 62.5 | 50.0 |
| Post-trial: Fair | 29.2 | 29.2 |
| Post-trial: Poor | 0 | 12.5 |
| Post-trial: Very poor | 0.0 | 0.0 |
An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.
| Participants | ETOR 75 DMSO | ETOR 75 PG (Pt 1) | ETOR 150 DMSO (Pt 1) | ETOR 150 PG (Pt 1) | ETOR OD (Pt 1) | Placebo (Pt 1) (Deviation) | ETOR 50 DMSO (Pt 2) | Placebo (Pt 2) |
|---|---|---|---|---|---|---|---|---|
| Study Parts 1 and 2: Number of Participants Who Experienced at Least One Adverse Event | 1 | 1 | 1 | 1 | 2 | 0 | 6 | 5 |
An adverse event is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.
| Participants | ETOR 75 DMSO | ETOR 75 PG (Pt 1) | ETOR 150 DMSO (Pt 1) | ETOR 150 PG (Pt 1) | ETOR OD (Pt 1) | Placebo (Pt 1) (Deviation) | ETOR 50 DMSO (Pt 2) | Placebo (Pt 2) |
|---|---|---|---|---|---|---|---|---|
| Study Parts 1 and 2: Number of Participants Who Discontinued Study Drug Due to an Adverse Event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Study Part 1: up to Day 47; Study Part 2: up to Day 28. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ETOR 75 DMSO (Pt 1) | — | 0/20 (0%) | 0/20 (0%) |
| ETOR 75 PG (Pt 1) | — | 0/20 (0%) | 0/20 (0%) |
| ETOR 150 DMSO (Pt 1) | — | 0/20 (0%) | 0/20 (0%) |
| ETOR 150 PG (Pt 1) | — | 0/18 (0%) | 1/18 (5.6%) |
| ETOR OD (Pt 1) | — | 0/2 (0%) | 2/2 (100%) |
| Placebo (Pt 1) (Deviation) | — | 0/2 (0%) | 0/2 (0%) |
| ETOR 50 DMSO (Pt 2) | — | 0/24 (0%) | 2/24 (8.3%) |
| Placebo (Pt 2) | — | 0/24 (0%) | 2/24 (8.3%) |
| Event | ETOR 75 DMSO (Pt 1) | ETOR 75 PG (Pt 1) | ETOR 150 DMSO (Pt 1) | ETOR 150 PG (Pt 1) | ETOR OD (Pt 1) | Placebo (Pt 1) (Deviation) | ETOR 50 DMSO (Pt 2) | Placebo (Pt 2) |
|---|---|---|---|---|---|---|---|---|
| Accidental overdoseInjury, poisoning and procedural complications | 0/20 | 0/20 | 0/20 | 0/18 | 2/2 | 0/2 | 0/24 | 0/24 |
| Urinary tract infectionInfections and infestations | 0/20 | 0/20 | 0/20 | 0/18 | 0/2 | 0/2 | 2/24 | 0/24 |
| Alanine aminotransferase increasedInvestigations | 0/20 | 0/20 | 0/20 | 0/18 | 0/2 | 0/2 | 1/24 | 2/24 |
| CholecystocholangitisHepatobiliary disorders | 0/20 | 0/20 | 0/20 | 1/18 | 0/2 | 0/2 | 0/24 | 0/24 |
| Age, Continuous(years) | Pt 1: ETOR 75 DMSO/ETOR 150 PG/ETOR 75 PG/ETOR 150 DMSO | Pt 1: ETOR 75 PG/ETOR 75 DMSO/ETOR 150 DMSO/ETOR 150 PG | Pt 1: ETOR 150 DMSO/ETOR 75 PG/ETOR 150 PG/ETOR 75 DMSO | Pt 1: ETOR 150 PG/ETOR 150 DMSO/ETOR 75 PG/ETOR 75 DMSO | Pt 1: ETOR OD/ ETOR 150 DMSO/ ETOR 75 DMSO/ ETOR 75 PG | Pt 1: Placebo (Deviation) | Pt 2: ETOR 50 DMSO | Pt 2: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 61.0 ± 6.6 | 61.0 ± 12.3 | 63.6 ± 10.6 | 62.0 ± 10.0 | 55.0 ± 8.5 | 60.5 ± 4.9 | 61.5 ± 8.2 | 61.2 ± 6.7 | 61.3 ± 7.8 |
| Sex: Female, Male(Participants) | Pt 1: ETOR 75 DMSO/ETOR 150 PG/ETOR 75 PG/ETOR 150 DMSO | Pt 1: ETOR 75 PG/ETOR 75 DMSO/ETOR 150 DMSO/ETOR 150 PG | Pt 1: ETOR 150 DMSO/ETOR 75 PG/ETOR 150 PG/ETOR 75 DMSO | Pt 1: ETOR 150 PG/ETOR 150 DMSO/ETOR 75 PG/ETOR 75 DMSO | Pt 1: ETOR OD/ ETOR 150 DMSO/ ETOR 75 DMSO/ ETOR 75 PG | Pt 1: Placebo (Deviation) | Pt 2: ETOR 50 DMSO | Pt 2: Placebo | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 3 | 4 | 3 | 1 | 0 | 18 | 15 | 48 |
| Male | 1 | 2 | 1 | 0 | 1 | 2 | 6 | 9 | 22 |
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2013 to primary completion in Nov 2014, 11 months.
Results were first posted in Dec 2015, 1 year after primary completion.
Of 25 phase 1/2 interventional studies under Osteoarthritis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etoricoxib